|
|
 |
|
Viewing report
|
|
|
|
Commercial Perspectives: Sleep Disorders - Insomnia, Narcolepsy and Restless Leg Syndrome
Datamonitor, Aug 2003, Pages: 88
Introduction
Sleep disorders, such as insomnia, narcolepsy and restless leg syndrome, are becoming an increasing focus for pharmaceutical manufacturers. Sanofi-Synthélabo is testimony to this with its insomnia drug Ambien (zolpidem), which now boasts blockbuster revenues. Different commercial opportunities exist in each of the analyzed sleep disorders for competing pharmaceutical manufacturers of all sizes.
Scope
- Analysis of the key epidemiological data points across each major pharmaceutical market for insomnia, narcolepsy and restless leg syndrome
- In-depth profiles of the current leading compounds in each sleep disorder, including future growth strategies, off-label case studies and R&D strategy
- Detailed coverage of the entire R&D pipelines for insomnia, narcolepsy and restless leg syndrome, including profiles of all leading candidates
- Comprehensive opinion leader research to compliment strategic recommendations for both marketed and pipeline drugs
Report Highlights
The entry of Pfizer into the insomnia market will generate a huge change in the current market dynamics. To continue to grow at a rapid rate, the market has to be driven through primary care physicians. The success of Pfizer in driving markets through primary care illustrates why Neurocrine chose Pfizer as a development partner for indiplon
Sanofi's Ambien will remain the market leader for the foreseeable future but its position will be threatened by the launch of Estorra, coupled with the patent expiry of the original brand in 2006. The company must learn from the introduction of other new versions of existing drugs in other CNS markets to maximize the potential of Ambien MR.
Reasons to Purchase
- Understand the epidemiological barriers to market growth in each highlighted sleep disorder
- Enhance your understanding of how the entry of Pfizer and other new players will impact the insomnia market
- Identify the likely market positions of future drugs, such as indiplon and Estorra
Customers who bought this item also bought
Sleep Disorders: Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking
Pipeline Insight: Insomnia - Targeting The Sleep Maintenance Market
Strategic Perspectives 2001: Restless Legs Syndrome - A Market Driven by Demographics
The 2009 World Market Forecasts for Imported Butadiene Rubber (BR)
Insomnia - Sanofi-Synthelabo to Drive Growth of This Potentially Lucrative Market
Restless Legs Syndrome - Recognition Lacking Still
Central Nervous System - Insomnia or Sleep Disorders Drug Pipeline Report
Br Malls Participacoes Sa
Br. Holdings Corporation
Strategic Perspectives 2001: Narcolepsy - Specific Drugs are Waking up the Market
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 World Forecasts of Butadiene Rubber (BR) Export Supplies
|
|
|
|
